The Chilean government announced last Friday free shipping from PrEP (PrEP), drugs that prevent HIV transmission; for first quarter of 2019.
For this reason, the Chilean authorities, a country which in the past seven years has seen a duplicate number of people infected with the virus, meet with members Integration and Homosexual Liberation Movement (Movilh), to define protocols that govern its use next year.
"PrEP pills can reduce the chance of contracting the virus by more than 90% during sexual practices if taken daily. Therefore, there must be a protocol that guides people about the real effects and encourages them to support safe sexual practices, because it is not the idea that pills cause relaxation, "said Health Area manager Movilh, Diego Ríos.
According to the Minister of Health, Emilio SantelicesPrEP pills are part of a new plan against AIDS and HIV, and will be applied as preventive treatment to high-risk populations.
How does it work?
According to the United States Centers for Disease Control and Prevention (CDC), if PrEP is consumed every day, you can reduced by more than 90% the possibility of contracting the virus that causes AIDS through sex or 70% by using needles that are not sterilized or used by many people.
PrEP contains emtricitabine and tenofovir, two drugs that are also used in ARVs because they reduce the amount of virus in the blood and prevent it from multiplying.
Pills do not work as vaccines, because they do not produce antibodies, but rather that their daily intake is needed so that emtricitabine and tenofovir are present in the blood at the time of infection and prevent HIV from forming in the body.
Before drinking it, it is important to verify the state of the kidneys and liver properly, because the pill can cause interference with these organs.
It is the US pharmaceutical company Gilead Sciences which began marketing this drug in 2012, under the brand name Truvada. The estimated commercial value of monthly maintenance reaches 600 dollars.
Years later, the World Health Organization (WHO) began recommending its use to prevent HIV among high-risk groups, such as sex workers or partners of infected patients.
According to figures from Onusida referring to 2017, in Chile there are 67,000 people infected with the HIV virus, of which 39,001 are under treatment, while projections show an increase of those affected at 100,000 by the end of this year.